Hoffmann-la Roche

This study is testing a medicine called emicizumab (Hemlibra) in babies from birth to 12 months old with severe hemophilia A. The goal is to see if a weekly or biweekly shot under the skin can prevent bleeding episodes and protect joints. About 55 infants will receive the drug fo…

This Phase 3 study tests crovalimab, a new injectable drug, against the current standard eculizumab in about 190 people with paroxysmal nocturnal hemoglobinuria (PNH). Participants are already on complement inhibitors and will be randomly assigned to switch to crovalimab or stay …

This trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 2…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This early-stage study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin, and the study will look for side effects and …

This phase II trial is testing an oral drug called giredestrant in 30 people with grade 1 endometrial cancer. The goal is to see if the drug can shrink or control the cancer over 6 months. Participants take one pill daily for up to 24 cycles, and doctors monitor tumor changes and…

This study tests a stem cell therapy called OpRegen for people with advanced dry age-related macular degeneration (geographic atrophy). Researchers inject retinal pigment epithelium cells derived from human embryonic stem cells into the eye to see if they can safely replace damag…

This study tests whether adding an experimental drug (RO7204239) that blocks myostatin—a protein that limits muscle growth—to the existing SMA medicine risdiplam (Evrysdi) can improve muscle strength and motor function. The trial includes 259 participants aged 2 to 25 with spinal…

This study tests the drug risdiplam (Evrysdi) in infants up to 6 weeks old who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The goal is to see if early treatment can help them reach motor milestones like sitting without support. The trial involve…

This phase 3 trial is testing whether a higher dose of ocrelizumab (Ocrevus) can better slow disability progression in adults with primary progressive multiple sclerosis compared to the standard dose. About 769 participants will receive either the approved 600 mg dose or a weight…

This study offers continued treatment with atezolizumab (Tecentriq) for cancer patients who were already receiving it in a prior Roche-sponsored trial. It includes 382 participants and aims to provide uninterrupted therapy while monitoring long-term safety and survival. The study…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already taking it in a previous Roche study and still benefiting. About 154 participants will receive pertuzumab every 3 weeks, alone or with other treatments, until th…

This Phase IV study is testing emicizumab (Hemlibra) in 136 people aged 13 to 70 with moderate or severe hemophilia A who do not have inhibitors. The goal is to see if this drug, given as a shot under the skin, can improve joint health, increase physical activity, and enhance ove…

This phase 3 trial is testing whether adding tiragolumab to the standard combination of atezolizumab and bevacizumab helps people with advanced liver cancer that cannot be surgically removed. About 687 participants will receive either the three-drug combo or the two-drug combo pl…

This Phase 3 study is testing whether Afimkibart can help people with moderate-to-severe ulcerative colitis achieve remission. About 400 participants will receive either the drug or a placebo. The main goals are to see if symptoms improve by week 12 and if remission lasts through…

This early-phase trial tests a new drug called zifibancimig for wet age-related macular degeneration (AMD), a leading cause of vision loss. The study involves 177 participants who receive the drug either as eye injections or through a surgically placed eye implant that releases t…

This Phase 2 trial tests fenebrutinib, an oral drug, in 109 people with relapsing multiple sclerosis. Participants receive either the drug or a placebo for 12 weeks, and researchers measure new brain lesions on MRI scans. The goal is to see if fenebrutinib can reduce disease acti…

This study tests an experimental drug called RO7126209 (Trontinemab) in people with early to moderate Alzheimer's disease. The drug is given by IV infusion and aims to reduce amyloid plaques in the brain, a hallmark of Alzheimer's. About 241 participants will receive either the d…

This study tests whether adding a new drug called inavolisib to two standard treatments (palbociclib and fulvestrant) can help people with a specific genetic mutation (PIK3CA) in advanced breast cancer live longer without their cancer growing. The trial includes 325 participants …

This phase 3 trial tests satralizumab, a drug that blocks a protein involved in inflammation, for people with moderate-to-severe thyroid eye disease. About 131 participants will receive either the drug or a placebo by injection. The main goal is to see if the drug reduces eye bul…

This study tests two experimental drug combinations (tobemstomig alone or with tiragolumab) against an approved drug (atezolizumab) in 204 people with advanced bladder cancer who cannot receive platinum-based chemotherapy. The goal is to see if the new combinations are safer and …

This study tests a drug called cevostamab in people with multiple myeloma that has returned or not responded to other treatments, including BCMA-targeted therapies. About 90 participants will receive the drug through an IV to see if it shrinks tumors and how safe it is. The goal …

This study tests whether adding tiragolumab to atezolizumab can help control esophageal cancer that hasn't grown after standard chemoradiotherapy. About 760 adults with inoperable esophageal squamous cell carcinoma will receive either the drug combination, atezolizumab alone, or …

This study compares two daily pills—fenebrutinib and teriflunomide—in about 746 adults with relapsing multiple sclerosis. The goal is to see which one better reduces relapses and delays worsening disability. Participants take one of the two drugs for several years, with an option…

This early-stage study tests a new medicine called RO7790121 in 50 adults with advanced liver scarring from MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body processes it. Researchers will also check if it can reduce liver stiffnes…

This study tests a drug called satralizumab in 30 children aged 8 to 17 with Duchenne muscular dystrophy (DMD). The goal is to see if it can improve bone density and help manage the disease. Participants continue their usual steroid treatment while receiving the study drug.

This study tests whether combining newer immunotherapy drugs with a standard targeted therapy (axitinib) can safely control advanced kidney cancer. About 199 adults with untreated, advanced clear-cell renal cell carcinoma will receive one of three drug combinations. The main goal…

This study tests a new once-daily medicine called RO7795081 for people with type 2 diabetes. About 240 adults will take either the new drug, a placebo (dummy pill), or an approved diabetes medicine (semaglutide) for 30 weeks. The main goal is to see if the new drug lowers blood s…

This study tests an experimental daily pill (RO7269162) in 256 people who either have brain plaques but no symptoms, or have mild memory problems due to Alzheimer's. Participants take the pill or a placebo for about 1.5 years, with regular check-ups to monitor safety and brain ch…

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can better shrink HER2-positive stomach or gastroesophageal junction cancer before surgery. About 42 adults with advanced but removable tumors will rec…

This study compares a new drug, divarasib, to two existing drugs (sotorasib and adagrasib) in people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C). The goal is to see if divarasib works better at slowing cancer growth or improving survival. Ab…

This phase 2 trial tests an experimental drug called tominersen in 301 people with early-stage Huntington's disease. The drug aims to lower levels of the mutant huntingtin protein, which is believed to cause the disease. Participants receive either tominersen or a placebo via inj…

This Phase 3 trial is testing whether a new drug combination (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a certain type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). The study inclu…

This Phase 3 study tests whether a new combination of drugs (mosunetuzumab plus lenalidomide) works better than the current standard (rituximab plus lenalidomide) for people with follicular lymphoma that has returned after at least one prior treatment. About 478 participants will…

This phase 2 trial tests a new immunotherapy drug called tobemstomig combined with chemotherapy (nab-paclitaxel) against the standard combination of pembrolizumab plus chemotherapy. It includes 83 people with previously untreated, PD-L1-positive, advanced triple-negative breast c…

This study tests a combination of two drugs, mosunetuzumab and lenalidomide, in people with follicular lymphoma, a type of blood cancer. The trial includes 237 participants and compares giving mosunetuzumab as an injection under the skin versus through an IV. The goal is to see i…

This study tests a gene therapy called delandistrogene moxeparvovec in 13 children under 4 years old with Duchenne muscular dystrophy. The goal is to see if it is safe and helps their muscles produce dystrophin, a protein they lack. Participants receive a single IV infusion and a…

This Phase 2 trial tests a drug called RO7204239 in 51 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. The drug is an antibody that blocks myostatin, a protein that normally limits muscle growth, to help pres…

This phase 3 trial tests whether satralizumab can prevent relapses in people with MOGAD, a rare disease where the immune system attacks the brain and spinal cord. About 152 participants aged 12 and older will receive either the drug or a placebo. The main goal is to see if satral…

This phase 2 trial tests whether prasinezumab, given as an IV infusion every 4 weeks, can slow motor decline in people with early Parkinson's disease. The study includes 586 participants who are already on stable Parkinson's medication. Researchers are measuring how long it takes…

This study tests a new once-daily pill called RO7795081 for weight loss in adults with obesity or overweight who also have weight-related health problems like high blood pressure or sleep apnea. The trial involves 352 participants and lasts 38 weeks, comparing the drug to a place…

This early-stage study tests the safety of an experimental drug called RO7669330, given as an injection into the eye, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The study involves 27 participants and will monitor side effects and eye he…

This study tests a drug called obinutuzumab for people with lupus nephritis, a kidney disease caused by lupus. About 271 participants receive either the drug or a placebo, added to their usual treatment. The goal is to see if the drug helps achieve complete kidney response, meani…

This study tests a new medicine, crovalimab, for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. It involves healthy volunteers and people with PNH to check safety and how well the drug works. The goal is to control the disease, not …

This study tested whether adding the immunotherapy drug atezolizumab to the targeted therapy trastuzumab emtansine (T-DM1) after surgery helps prevent breast cancer from returning in people with HER2-positive breast cancer who still had cancer cells after initial treatment. About…

This study follows about 1,300 people with multiple sclerosis who are already taking ocrelizumab to see how safe and effective it is over many years. Participants continue their usual treatment, and researchers track side effects, disability changes, and brain scans. The goal is …

This study tests whether adding the immunotherapy drug atezolizumab to standard targeted therapy (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. It includes about 557 adults whose cancer worsened after initial treatment with atezolizumab and bevaciz…

This study tested two oral drugs, alectinib and crizotinib, in 187 Asian patients with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer) who had not received prior treatment. The goal was to see which drug better delayed cancer growth. Patients too…

This study compares a targeted drug (alectinib) taken as a pill for 2 years against standard chemotherapy after surgery for a specific type of lung cancer (ALK-positive). About 257 adults with stage IB to IIIA lung cancer that was fully removed will participate. The goal is to se…

This study tests whether adding an experimental drug (RO7204239) to an existing weight-loss medication (tirzepatide) helps adults with obesity or overweight lose more weight over 48 weeks. About 285 participants without diabetes will receive either the combination or a placebo pl…

This study tests the safety of combining the targeted drug alectinib with chemotherapy in people who have had surgery for a specific type of lung cancer (ALK-positive non-small cell lung cancer). The 11 participants received up to four cycles of the drug combo after their tumor w…

This study tests whether adding the drug giredestrant to standard treatment (Phesgo) can help people with advanced HER2-positive, estrogen receptor-positive breast cancer live longer without their cancer getting worse. About 922 participants who have not had prior treatment for a…

This study aimed to see if adding the targeted drug inavolisib to standard chemotherapy and bevacizumab could help people with a specific genetic form of advanced colorectal cancer (PIK3CA-mutated). It was designed for adults who had not yet received treatment for metastatic dise…

This study tests whether a higher dose of the drug ocrelizumab can better control relapsing multiple sclerosis (MS) and delay disability compared to the standard dose. About 864 adults with relapsing MS will receive either the higher or standard dose every 24 weeks. The main goal…

This study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a fast-growing type of lymphoma that has a high risk of coming back. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 ad…

This study offers continued access to the cancer drug atezolizumab for patients who were already benefiting from it in a previous Roche-sponsored trial. Around 1,000 participants who cannot get the drug locally can keep receiving it. The main goal is to provide ongoing treatment …

This study tests a new experimental drug, englumafusp alfa, combined with two other drugs (obinutuzumab and glofitamab) in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to prior treatments. The goal is to see if the combination is safe and can shrin…

This study tests different treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are grouped by specific genetic markers (biomarkers) to see which therapy works best for their cancer type. The main goal is to see how long …

This study tests several targeted therapies for people with advanced or metastatic non-small cell lung cancer. Researchers use a simple blood test to find specific genetic changes in the cancer, then match patients to a treatment that targets those changes. The goal is to shrink …

This study tests whether crovalimab works as well as eculizumab for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. About 210 adults who have not had prior complement inhibitor therapy will receive either drug. The main goals are to see if crovalimab…

This study tests a new medicine called crovalimab for people with a rare disease called atypical hemolytic uremic syndrome (aHUS), which causes blood clots and kidney damage. The trial includes 83 adults and teens who receive the drug to see if it can control the disease and impr…

This study compares a new drug, tobemstomig, combined with chemotherapy against the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if the new combination works better a…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests whether ocrelizumab is safer and more effective than fingolimod for children and adolescents (ages 10 to under 18) with relapsing-remitting multiple sclerosis. Participants receive either drug and are monitored for relapses and brain lesions over at least 24 week…

This study tests a refillable eye implant (Port Delivery System) that slowly releases medication to treat wet age-related macular degeneration, a leading cause of vision loss. About 451 adults aged 50 and older who have already responded to standard injections will receive refill…

This early-stage study tests an experimental drug called RO7567132, alone or with another drug (atezolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shr…

This study tests the drug ocrelizumab in 927 adults with progressive multiple sclerosis (MS), a condition that steadily worsens over time. The goal is to see if the drug can slow or stop disability progression, reduce relapses, and control brain lesions over 4 years. Participants…

This phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than a standard chemotherapy regimen for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. About 208 adu…

This study aimed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in people with antiphospholipid syndrome (APS). APS is an autoimmune disease that increases clot risk. The trial was withdrawn before enrolling any participants, so no re…

This study tests an experimental drug called RO7790121 in about 21 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and stomach pain. Partic…

This study compares a new drug, fenebrutinib, to an approved medication (teriflunomide) in 751 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take one of the two pills daily…

This study compares two treatments for primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens over time. About 985 adults with PPMS will receive either a daily pill called fenebrutinib or an infusion of ocrelizumab, the current standard therapy. The goa…

This study tests a drug called crovalimab in about 50 people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. Participants must be at least 12 years old, weigh 40 kg or more, and have not received prior complement inhibitor treat…

This study tests the safety and dosing of ocrelizumab in 23 children and teens (ages 10–18) with relapsing-remitting multiple sclerosis over 2 years. The goal is to find the best dose for a future larger study. Participants receive the drug and are monitored for side effects and …

This study tests an experimental drug called prasinezumab in 316 people with early Parkinson's disease. The drug is an antibody designed to target and remove clumps of a protein linked to Parkinson's. Participants receive either the drug or a placebo for 52 weeks, with an option …

This study tests whether adding the experimental drug glofitamab to standard chemotherapy (gemcitabine plus oxaliplatin) helps people with relapsed or refractory diffuse large B-cell lymphoma live longer compared to the current standard treatment (rituximab plus the same chemo). …

This study tests a new drug called glofitamab, alone or with another drug (obinutuzumab), in people with B-cell non-Hodgkin's lymphoma that has come back or not responded to previous treatments. The goal is to find the safest and most effective dose and see how well it shrinks tu…

This study tests whether a newer targeted drug, entrectinib, works better than the current standard drug, crizotinib, for people with advanced lung cancer that has a specific genetic change (ROS1). About 220 participants will take one of the two pills daily. The study focuses on …

This study tests whether faricimab, an eye injection, can be given as infrequently as every 24 weeks to people with wet age-related macular degeneration (nAMD) who have not been treated before. The goal is to see if it keeps vision stable and reduces the need for more frequent sh…

This study tests several targeted treatments for people with rare ovarian cancers that have come back or not gone away. Researchers choose the treatment based on specific markers found in each person's tumor. The goal is to see if these drugs can shrink or control the cancer. Abo…

This study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. Participants receive either the drug or a placebo to see if it reduces eye bulging by at least 2 millimeters over 24 weeks. T…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests whether the drug atezolizumab can help prevent non-small cell lung cancer from coming back after surgery and chemotherapy. About 1,280 people with stage IB to IIIA lung cancer took part. Half received atezolizumab for about a year, and half received standard moni…

This study tests a new medicine called Afimkibart (RO7790121) for people with moderate to severe eczema (atopic dermatitis). About 160 adults will receive either the drug or a placebo to see if it improves skin symptoms like redness and itching. The main goal is to measure at lea…

This early-phase study tests a drug called inavolisib, alone or with atezolizumab, in people with cancers that have a specific change in the PIK3CA gene. The study includes patients with head and neck cancer that has returned or spread. The main goals are to check safety and see …

This study tests a drug called entrectinib in people with advanced cancers that have certain gene changes (NTRK, ROS1, or ALK). About 534 adults with 15 different cancer types will take the pill daily. The goal is to see if the drug shrinks tumors and how long that effect lasts.

This study tests whether ocrelizumab (Ocrevus) can slow disability worsening in adults with primary progressive multiple sclerosis (PPMS), including those with more advanced disease. About 1,000 participants receive either the drug or a placebo, and researchers measure changes in…

This study tests a drug called obinutuzumab in 303 people with active lupus. Participants receive either the drug or a placebo, along with their usual treatments. The goal is to see if obinutuzumab can reduce lupus symptoms and disease activity better than placebo alone.

This study tests a drug called atezolizumab in 60 people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. Participants have not received prior treatment for their advanced cancer. The goal is to see if the drug helps them live longer and co…

This study is collecting long-term data from about 6,000 patients in routine clinical practice who are receiving Roche eye medications (Faricimab or the Port Delivery System with Ranibizumab) for conditions like wet age-related macular degeneration, diabetic macular edema, and re…

This study is watching nearly 3,000 people newly diagnosed with breast cancer in Latin America. It does not test a new treatment but instead collects information on how the cancer is diagnosed, what treatments are used, and how patients do over time. The goal is to better underst…

This study observes 44 people with type 3 von Willebrand disease, a rare bleeding disorder, who are already on standard preventive treatment. Researchers will track how often bleeding episodes occur and how the condition affects quality of life over at least 24 weeks. No new drug…

This study follows about 800 people with ALK-positive advanced non-small cell lung cancer who are taking the drug alectinib as part of their routine care. Researchers want to see how long the cancer stays under control and how patients are managed in real-world clinics, not just …

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …

This study follows 1,000 Chinese adults with diffuse large B-cell lymphoma (a fast-growing blood cancer) who are receiving polatuzumab as part of their routine care. Researchers are tracking how long patients stay cancer-free after treatment and noting any side effects. The goal …